Literature DB >> 22048117

Buruli ulcer.

Thorbjorg Einarsdottir1, Kris Huygen.   

Abstract

Buruli Ulcer (BU) is a neglected, necrotizing skin disease, caused by M. ulcerans, that can leave patients with prominent scars and lifelong disability. M. ulcerans produces a diffusible lipid toxin, mycolactone, essential for bacterial virulence. Prevention is difficult as little is known about disease transmission and there is no vaccine. There have been several recent advances in the field. These include sequencing of the bacterial genome and of the giant plasmid responsible for mycolactone synthesis, better understanding of the bacterial lifecycle and of the mechanism of action of the toxin. This work has revealed a number of possible vaccine candidates, some of which are shared with other mycobacteria, e.g. M. tuberculosis, while other targets are unique to M. ulcerans. In this review, we discuss several M. ulcerans vaccine targets and vaccination methods, and outline some of the gaps in our understanding of the bacterium and the immune response against it.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22048117     DOI: 10.4161/hv.7.11.17751

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  16 in total

1.  The use of ozone therapy in Buruli ulcer had an excellent outcome.

Authors:  Antonella Bertolotti; Annunziata Izzo; Pier Giovanni Grigolato; Maria Letizia Iabichella
Journal:  BMJ Case Rep       Date:  2013-01-31

2.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

3.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

4.  In-vitro activity of avermectins against Mycobacterium ulcerans.

Authors:  Till F Omansen; Jessica L Porter; Paul D R Johnson; Tjip S van der Werf; Ymkje Stienstra; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2015-03-05

5.  Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.

Authors:  Bryan E Hart; Laura P Hale; Sunhee Lee
Journal:  PLoS Negl Trop Dis       Date:  2015-09-22

6.  Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease.

Authors:  Miriam Bolz; Sarah Kerber; Gert Zimmer; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2015-08-14

7.  Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.

Authors:  Virginie Roupie; Sacha J Pidot; Tobba Einarsdottir; Christophe Van Den Poel; Fabienne Jurion; Timothy P Stinear; Kris Huygen
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

8.  Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice.

Authors:  Raphael Bieri; Miriam Bolz; Marie-Thérèse Ruf; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2016-02-10

9.  Mycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcer.

Authors:  U Anand; M Sinisi; M Fox; A MacQuillan; T Quick; Y Korchev; C Bountra; T McCarthy; P Anand
Journal:  Mol Pain       Date:  2016-06-20       Impact factor: 3.395

10.  Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.

Authors:  Miriam Bolz; Angèle Bénard; Anita M Dreyer; Sarah Kerber; Andrea Vettiger; Wulf Oehlmann; Mahavir Singh; Malcolm S Duthie; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2016-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.